A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• KRAS mutations are prevalent in pancreatic cancer, posing treatment challenges.
• RAF inhibitors are potential therapeutic agents, but selective BRAF inhibitors can paradoxically activate signaling.
• Pan-RAF inhibitor LY3009120 offers an alternative for KRAS-mutant tumors.

Purpose of the Study:

• To explore a novel combination therapy for pancreatic cancer using a YAP inhibitor and LY3009120.
• To investigate the role of YAP in pancreatic cancer progression and response to RAF inhibition.
• To validate YAP inhibition as a strategy to enhance LY3009120 efficacy.

Main Methods:

• Assessed YAP expression correlation with patient survival.
• Utilized stable YAP knockdown to evaluate its impact on tumor growth.
• Investigated the effect of LY3009120 in combination with YAP knockdown or inhibition.
• Analyzed the modulation of AKT signaling pathways.

Main Results:

• Reduced YAP expression correlated with improved patient outcomes.
• YAP knockdown significantly inhibited pancreatic cancer cell proliferation and tumor growth.
• LY3009120 combined with YAP knockdown demonstrated enhanced antitumor effects.
• YAP depletion prevented AKT pathway activation following LY3009120 treatment.
• Combination therapy with YAP inhibitor verteporfin and LY3009120 improved efficacy.

Conclusions:

• YAP inhibition, genetically or pharmacologically, sensitizes pancreatic cancer to LY3009120.
• This sensitization occurs by blocking compensatory AKT signaling.
• The combination of YAP inhibition and LY3009120 presents a validated therapeutic strategy for KRAS-mutant pancreatic cancer.